Amphastar Pharmaceuticals, Inc. (AMPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMPH POWR Grades
- Growth is the dimension where AMPH ranks best; there it ranks ahead of 98.66% of US stocks.
- AMPH's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
- AMPH's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).
AMPH Stock Summary
- AMPH's current price/earnings ratio is 381.46, which is higher than 97.83% of US stocks with positive earnings.
- In terms of twelve month growth in earnings before interest and taxes, Amphastar Pharmaceuticals Inc is reporting a growth rate of -92.38%; that's higher than just 20.92% of US stocks.
- In terms of volatility of its share price, AMPH is more volatile than only 3.08% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Amphastar Pharmaceuticals Inc, a group of peers worth examining would be IRMD, KRNT, ELF, NATI, and SSTI.
- Visit AMPH's SEC page to see the company's official filings. To visit the company's web site, go to www.amphastar.com.
AMPH Price Target
For more insight on analysts targets of AMPH, see our AMPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $21.60 | Average Broker Recommendation | 1.79 (Moderate Buy) |
AMPH Stock Price Chart Interactive Chart >
AMPH Price/Volume Stats
| Current price | $20.01 | 52-week high | $22.69 |
| Prev. close | $19.98 | 52-week low | $16.91 |
| Day low | $19.84 | Volume | 145,693 |
| Day high | $20.15 | Avg. volume | 188,986 |
| 50-day MA | $18.59 | Dividend yield | N/A |
| 200-day MA | $18.93 | Market Cap | 953.18M |
Amphastar Pharmaceuticals, Inc. (AMPH) Company Bio
Amphastar Pharmaceuticals focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company was founded in 1996 and is based in Rancho Cucamonga, California.
AMPH Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $20.01 | $23.86 | 21% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Amphastar Pharmaceuticals Inc. To summarize, we found that Amphastar Pharmaceuticals Inc ranked in the 59th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 21.67%. The most interesting components of our discounted cash flow analysis for Amphastar Pharmaceuticals Inc ended up being:
- The business' balance sheet suggests that 6% of the company's capital is sourced from debt; this is greater than just 20.65% of the free cash flow producing stocks we're observing.
- AMPH's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 44.77% of tickers in our DCF set.
- As a business, Amphastar Pharmaceuticals Inc experienced a tax rate of about 31% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 91.81% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 19% |
| 1% | 20% |
| 2% | 21% |
| 3% | 22% |
| 4% | 23% |
| 5% | 25% |
DVA, HZNP, ESMC, JAZZ, and PRAH can be thought of as valuation peers to AMPH, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Latest AMPH News From Around the Web
Below are the latest news stories about Amphastar Pharmaceuticals Inc that investors may wish to consider to help them evaluate AMPH as an investment opportunity.
Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation ConferenceRANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will be presenting at the Human Health Innovation Conference on Tuesday, June 22, 2021, at 2:00 pm Eastern time. This presentation |
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceRANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:30 pm Eastern time. This presentation will be made available webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation. About Amphastar: Amphastar is a specialty pharmaceutical com... |
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of... |
Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare ConferenceRANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time. This presentation will be made available webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation. About Amphastar: Amphastar is a specialty pharmaceutical company that f... |
FDA Approves New Drug Application For Amphastar’s Dextrose InjectionAmphastar Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Dextrose injection 50% in the 50 ml Luer-Jet Prefilled Syringe System. Amphastar (AMPH) has sold and marketed the injection under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program over the last 40 years. Notably, the Dextrose injection generated net revenues of $7.6 million for the year ended Dec. 31, 2020. Amphastar CEO Dr. |
AMPH Price Returns
| 1-mo | 0.25% |
| 3-mo | 11.73% |
| 6-mo | 5.54% |
| 1-year | -0.94% |
| 3-year | 18.54% |
| 5-year | 33.40% |
| YTD | -0.50% |
| 2020 | 4.25% |
| 2019 | -3.07% |
| 2018 | 3.43% |
| 2017 | 4.45% |
| 2016 | 29.44% |
Continue Researching AMPH
Want to see what other sources are saying about Amphastar Pharmaceuticals Inc's financials and stock price? Try the links below:Amphastar Pharmaceuticals Inc (AMPH) Stock Price | Nasdaq
Amphastar Pharmaceuticals Inc (AMPH) Stock Quote, History and News - Yahoo Finance
Amphastar Pharmaceuticals Inc (AMPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...